<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076516</url>
  </required_header>
  <id_info>
    <org_study_id>ALV-01</org_study_id>
    <nct_id>NCT02076516</nct_id>
  </id_info>
  <brief_title>Pilot Evaluation Of CORACTO® (THE PILOT-SECRET TRIAL)</brief_title>
  <acronym>PILOT-SECRET</acronym>
  <official_title>Pilot Evaluation Of CORACTO® (Rapamycin-Eluting Coronary Stent Delivery System) in The Treatment Of Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alvimedica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alvimedica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the CORACTO®&#xD;
      (Rapamycin®-Eluting coronary stent delivery system) for the treatment of up to two de novo&#xD;
      lesions or restenotic post-PTCA (non-stented) lesions located in up to two epicardial native&#xD;
      coronary arteries (maximum one lesion per vessel) suitable for treatment with stents from 2.5&#xD;
      to 4.0 mm in diameter &lt; than 15 mm suitable for treatment with a single CORACTO® stent in a&#xD;
      population of 100 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent late loss (LL) in patients implanted with a CORACTO® stent (per protocol analysis)</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis ( Definite and probable)</measure>
    <time_frame>at 30 days, 6 months and 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Device-oriented Target Lesion Failure (TLF)</measure>
    <time_frame>at 30 days, 6 months and 12 months</time_frame>
    <description>Device-oriented Target Lesion Failure (TLF) defined as the composite of Cardiac Death, Target Vessel Myocardial Infarction (TV-MI), Clinically indicated Target lesion Revascularization (CI-TLR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Oriented Composite Endpoint Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>at 30 days, 6 months and 12 months</time_frame>
    <description>Patient Oriented Composite Endpoint Major Adverse Cardiac Events (MACE) defined as any cause mortality, Myocardial Infarction MI (Q-wave and non-Q-wave) or any clinically indicated Target Vessel Revascularization</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Revascularization Rate (clinically and non-clinically driven)</measure>
    <time_frame>at 30 days, 6months and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of uncovered struts at Follow Up (as measured at FU Optical Coherence Tomography (OCT) imaging)</measure>
    <time_frame>at 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Late-appearing stent malapposition (as documented from post- and FU Optical Coherence Tomography (OCT) imaging and expressed both as dichotomous and continuous manner [number / percentage of late-appearing malapposed struts])</measure>
    <time_frame>at 6 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Drug-eluting stent: CORACTO®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arrm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-eluting stent: CORACTO®</intervention_name>
    <arm_group_label>Drug-eluting stent: CORACTO®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is ≥ 18 years old.&#xD;
&#xD;
          -  Patient is eligible for percutaneous coronary intervention (PCI) and acceptable&#xD;
             candidate for coronary artery bypass grafting (CABG).&#xD;
&#xD;
          -  Clinical evidence of ischemic heart disease and/or a positive functional study, stable&#xD;
             angina pectoris (Canadian Cardiovascular Society Classification (CCS) 1, 2, 3 or 4) or&#xD;
             unstable angina pectoris (Braunwald Class IB-C, IIB-C, or IIIB-C), or silent ischemia.&#xD;
&#xD;
          -  The target lesion(s) or target vessel(s) meet(s) all the following criteria:&#xD;
&#xD;
               1. The target lesion is a single de novo lesion in a native coronary artery.&#xD;
&#xD;
               2. The stenosis of target lesion(s) is ≥ 50% and &lt; 100% (by visual estimation).&#xD;
&#xD;
               3. The target lesion length must be ≤ 15 mm. In case that a second stent should be&#xD;
                  required for successful treatment, it should be a CORACTO® stent.&#xD;
&#xD;
               4. The target reference vessel diameter must be (by visual estimation) suitable for&#xD;
                  treatment with stents between 2.5 and 4.0 mm.&#xD;
&#xD;
          -  Patient has been informed of the nature of the study, understands the study&#xD;
             requirements, agrees to its provisions and has provided written informed consent as&#xD;
             approved by the Institutional Review Board/Ethics Committee of the respective clinical&#xD;
             site.&#xD;
&#xD;
          -  The patient is willing and able to comply with all specified follow-up evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Most recent left ventricular ejection fraction (LVEF) of the patient is &lt; 25%.&#xD;
&#xD;
          -  Known allergies to the following: aspirin, Clopidogrel bisulfate (Plavix®), Prasugrel&#xD;
             (Effient®) or Ticlopidine (Ticlid®), heparin, Rapamycin, stainless steel, Poly Lactic&#xD;
             - co- glycolic acid or contrast agent (that cannot be adequately premedicated).&#xD;
&#xD;
          -  Platelet count is less than 100,000 cells/mm3 or more than 700,000 cells/mm3.&#xD;
&#xD;
          -  White Blood Cell count is less than 3,500 cells/mm3.&#xD;
&#xD;
          -  Evidence of an ST-segment elevation acute myocardial infarction (MI) or non-ST segment&#xD;
             elevation MI with positive Troponin within 72 hours before the intended treatment.&#xD;
&#xD;
          -  ANY previous PCI&#xD;
&#xD;
          -  Planned staged procedures (patient with 2-vessel disease should be treated during the&#xD;
             same procedure). Presence of any other significant lesion of &gt; 50% stenosis (by visual&#xD;
             estimation) anywhere within the target vessel&#xD;
&#xD;
          -  Significant lesions in any non-target vessel that will require interventional&#xD;
             treatment within 30 days post-procedure&#xD;
&#xD;
          -  Planned future interventional procedure in the target vessel .&#xD;
&#xD;
          -  The target lesion(s) require(s) treatment with a device other than PTCA balloon prior&#xD;
             to stent placement. (e.g. but not limited to directional coronary atherectomy, excimer&#xD;
             laser, rotational atherectomy, thrombus aspiration etc.).&#xD;
&#xD;
          -  Previous stenting anywhere within the target vessel(s)&#xD;
&#xD;
          -  Target vessel has evidence of thrombus&#xD;
&#xD;
          -  Excessive tortuosity (&gt; 60°) of the target vessel proximal to the target lesion (by&#xD;
             visual estimation).&#xD;
&#xD;
          -  The target lesion(s) has any of the following characteristics (by visual estimation):&#xD;
&#xD;
               1. Ostial or bifurcation lesion (within 3mm from region of origin of target vessel,&#xD;
                  by visual estimation).&#xD;
&#xD;
               2. Target lesion involves a side branch &gt; 2mm in diameter.&#xD;
&#xD;
               3. Moderate to severely calcified lesion which cannot be successfully predilated.&#xD;
&#xD;
               4. Target lesion is located in or supplied by an arterial or venous bypass graft.&#xD;
&#xD;
               5. A complete occlusion (TIMI flow 0 or 1).&#xD;
&#xD;
          -  Target lesion is located in left main trunk.&#xD;
&#xD;
          -  Stroke or transient ischemic attack within 180 days prior to the baseline procedure.&#xD;
&#xD;
          -  Active peptic ulcer or upper GI bleeding within 180 days prior to the baseline&#xD;
             procedure.&#xD;
&#xD;
          -  The patient has bleeding haemorrhagic diathesis or coagulopathy.&#xD;
&#xD;
          -  The patient will refuse a blood transfusion.&#xD;
&#xD;
          -  The patient has a widespread peripheral vascular disease.&#xD;
&#xD;
          -  Acute or chronic renal dysfunction (creatinine clearance below 40ml/m2).&#xD;
&#xD;
          -  The patient requires multiple stent implantations for a tandem lesion.&#xD;
&#xD;
          -  Life expectancy less than 1 year.&#xD;
&#xD;
          -  Patient is currently participating in an investigational drug or device study that has&#xD;
             not completed the primary endpoint or that clinically interferes with the current&#xD;
             study endpoints.&#xD;
&#xD;
          -  In the Investigator's opinion patient has (a) co-morbid condition(s) that could limit&#xD;
             the patient's ability to participate in the study, compliance with follow-up&#xD;
             requirements or impact the scientific integrity of the study.&#xD;
&#xD;
          -  Female of childbearing potential, pregnant and breastfeeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Javier Escaned, MD</last_name>
    <email>escaned@secardiologia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>ZNA Middleheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Verheye, MD</last_name>
      <email>stefan.verheye@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Stefan Verheye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38028</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Faurie, MD</last_name>
      <email>faurieb@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Benjamin Faurie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Prive Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Louvard, MD</last_name>
      <email>y.louvard@icps.fr</email>
    </contact>
    <investigator>
      <last_name>Yves Louvard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Fernández, BSc/MSc</last_name>
      <email>javier.escaned@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Javier Escaned</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bezmialem University Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Omer Goktekin, Prof Dr</last_name>
      <email>ogoktekin@ogu.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Omer Goktekin, Prof Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>February 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>February 28, 2014</last_update_submitted>
  <last_update_submitted_qc>February 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-eluting Stent,Coronary Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

